retinoic acid early transcript 1M (pseudogene)Genealiases: []
Q-omics provides the consensus-scored RAET1M profile across patient tissues and cancer cell-line models. RAET1M expression is associated with patient survival in 12 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, RAET1M is differentially expressed in 3, with the highest sampling consensus in LUSC. Additionally, RAET1M RNA expression shows 6,469 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight KIRC, LUSC, and STAD as cancer lineages where RAET1M shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RAET1M — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RAET1M survival associations across molecular data types. RAET1M RNA expression shows survival associations in the most cancer types (12). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RAET1M RNA expression–survival associations across cancer types. High RAET1M expression shows unfavorable associations in KIRC, LUAD, THCA, ACC and COAD, but favorable associations in OV. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .010). Together, the overview and detailed table identify KIRC as the clearest survival context for RAET1M RNA expression.
This table summarizes RAET1M tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 3. The strongest signals are observed in LUSC for RNA.
This table ranks reproducible tumor–normal expression differences for RAET1M. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RAET1M shows higher tumor expression in LUSC, HNSC and KIRP. The LUSC box plot shows higher RAET1M RNA expression in tumor versus normal tissue (log2 FC = +0.014, t-test p = .046).
This table shows molecular features associated with RAET1M in patient tissues and cancer cell lines. In patient samples, RAET1M shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
